Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

Brigatinib a potential standard treatment alternative for treatment-naive ALK+ NSCLC
30 Apr 2022
bởiAudrey Abella
In patients with advanced anaplastic lymphoma kinase-positive non-small cell lung cancer (ALK+ NSCLC) who were ALK inhibitor-naïve, brigatinib showed superior efficacy and safety over crizotinib, according to the final results of the phase III ALTA-1L* trial presented at ELCC 2022.
30 Apr 2022

Parathyroidectomy does not lessen morbidity, mortality in mild hyperparathyroidism
29 Apr 2022
Parathyroidectomy (PTX) seems ineffective at reducing morbidity or mortality in patients with mild primary hyperparathyroidism (PHPT) relative to observation without intervention, suggests a study. For at least a decade, observation has seen no evidence of adverse effects regarding mortality, fractures, cancer, cardiovascular (CV) and cerebrovascular (CBV) events, or renal morbidities.
29 Apr 2022






